Actinium Pharmaceuticals (NYSE:ATNM) Trading Down 0.7% – Here’s What Happened

Posted by ABMN Staff on Dec 11th, 2025

Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) shares fell 0.7% on Wednesday . The stock traded as low as $1.41 and last traded at $1.42. 155,911 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 344,008 shares. The stock had previously closed at $1.43.

Actinium Pharmaceuticals Price Performance

The company has a market cap of $44.30 million, a P/E ratio of -1.02 and a beta of -0.37. The firm’s 50-day moving average is $1.44 and its two-hundred day moving average is $1.56.

Institutional Trading of Actinium Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Nuveen LLC purchased a new position in Actinium Pharmaceuticals in the first quarter worth about $239,000. Charles Schwab Investment Management Inc. raised its position in Actinium Pharmaceuticals by 35.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 97,604 shares of the company’s stock valued at $157,000 after purchasing an additional 25,511 shares during the period. Callan Family Office LLC bought a new stake in shares of Actinium Pharmaceuticals in the 1st quarter valued at approximately $38,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Actinium Pharmaceuticals in the 2nd quarter valued at approximately $91,000. Finally, Invesco Ltd. boosted its holdings in shares of Actinium Pharmaceuticals by 1,135.9% in the 1st quarter. Invesco Ltd. now owns 153,555 shares of the company’s stock worth $247,000 after purchasing an additional 141,130 shares during the period. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

(Get Free Report)

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).